Compare Aptiv PLC (APTV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Novavax Inc — how do they compare? Aptiv PLC trades at $60.46 (market cap $12.82B), while Novavax Inc trades at $9.19 (market cap $1.53B). The key difference: Aptiv PLC is far larger — about 8.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| APTV | NVAX | |
|---|---|---|
Market Cap | $12.82B | $1.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $11.19 |
52-Week Low | $52.57 | $6.22 |
Enterprise Value | $19.53B | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $60.57, up 1.19% with a bearish technical signal but strong analyst support. Recent earnings beats and a consensus price target of $78.57 suggest upside potential. Revenue grew to $20.40B in 2025, though net margins compressed to 1.77%. The company announced Q2 2026 results on August 4, 2026, with expectations of $1.42 EPS.
Outlook is mixed: bullish fundamentals from earnings momentum and low P/S of 0.64 contrast with technical weakness and margin pressures. Risks include debt levels and competitive threats, but institutional buy ratings (63.6%) highlight confidence in long-term growth from automotive technology demand.
Novavax (NVAX) trades at $9.33, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $14.00. The company reported revenue of $1.12 billion in 2025, swinging to a net income of $440.30 million, but faces negative cash flow and a negative shareholder equity position. Recent news highlights shareholder dissent at the AGM and investor attention amid vaccine stock volatility.
The outlook is mixed: strong valuation ratios and recent earnings beats suggest upside potential, but persistent cash burn and competitive pressures in the vaccine market pose significant risks. Analyst sentiment is predominantly bullish, yet the stock's performance remains sensitive to clinical developments and market sentiment toward biotech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
